Lastly, Pfizer is a solid dividend stock. It now offers a beefy 6.8% yield, and has increased its payouts by 53.6% in the ...

Yet oncology products have a greater likelihood than other therapy areas to fail at Phase III (see graph) – well after the branding process has already begun and market expectations are somewhat ...

"As we advance our broader strategy to build a leading injectables portfolio with durable, high-impact complex products, we are excited to announce the U.S. launch of Boruzu in our oncology portfolio.

Jim Furniss and Chris Teale discuss the market access environment for new oncology products in Europe, including sales comparisons with the US and their thoughts on the future. What do we mean by ...

Predictive Oncology shares are trading higher on Tuesday after the company announced it developed predictive models to target ...

Kanvas Biosciences’ new research suggests that the company’s HiPR-Map Platform is capable of outperforming traditional ...

with a proven track record of driving revenue growth and expanding market presence for various oncology products. He has held senior positions at major pharmaceutical companies like Bayer ...

Limited (LON:HCM – Get Free Report) passed below its 200-day moving average during trading on Monday . The stock has a 200-day moving average of GBX 258.58 ($3.34) and traded as low as GBX 231 ($2.98) ...